Praluent’s Price Cut: Testing The Tech Model For Drug Pricing
Executive Summary
It may be more accident than design, but Sanofi and Regeneron are applying a tried and true pricing model to Praluent. Just ask tech companies.
You may also be interested in...
Praluent Pricing: Collaboration With ICER Sets A New Standard
Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.
The Next PCSK-9 Pricing Debate: PBM Says Outcomes Data Should Mean Deeper Discount
Express Scripts expects to negotiate a lower price per patient for Amgen’s Repatha assuming the drug shows benefits in a 27,500-patient outcomes trial. Critics of the PBM and its practices, however, may help industry push back against the idea that greater benefit means lower prices.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.